311

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

INDUSTRY SPONSORED SYMPOSIA

pageSunday, June 1, 2014 13:15 - 15:15Auditorium Fresenius Medical Care 312Elicium 2 Amgen 313 Elicium 1 Gambro 314Forum Otsuka Pharmaceuticals Europe 315E104-107 Vifor Fresenius Medical Care Renal Pharma 316G106-107 Keryx Biopharmaceuticals 317G104-105 AbbVie 318G102-103 B.Braun 319

18:45 - 19:45G102-103 Alexion Pharma International 320

Monday, June 2, 2014 06:45 - 07:45 G104-105 AbbVie 321

13:15 - 15:15Auditorium Fresenius Medical Care Renal Pharma 322Elicium 2 Baxter 323Elicium 1 Sanofi 324E104-107 Novartis 325G106-107 Asahi Kasei Medical 326G104-105 Pharmacosmos 327G102-103 ZS Pharmaceuticals 328Emerald Chiesi Farmaceutici 329

312

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15Auditorium

Unravelling Vascular Calcification Processes in Search of Advanced Therapeutic Avenues for CKD Patients

Chairs: Bernard Canaud, Bad Homburg, Germany Andreas Pasch, Basel, Switzerland

Pathogenesis of Vascular Calcification: Phosphate or calciprotein particles - who is the cul-prit?Makoto Kuro-O, Yakushiji Shimotsuke, Japan

Ascertaining the Vascular Calcification Risk: The Role of Non-Invasive Imaging Techniques Paolo Raggi, Alberta, Canada

Reducing the Vascular Calcification and Cardiovascular Burden in Renal Replacement The-rapy: Potential of Convective Treatment ModalitiesJeroen Kooman, Maastricht, The Netherlands

Concluding RemarksAndrea Pasch, Basel, Switzerland

Organised by FRESENIUS MEDICAL CARE

313

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15Elicium 2

Management of CKD-MBD and renal anaemia: new considerations in 2014

Chair: Charles A. Herzog, Minneapolis, USA

Cardiovascular risk in CKD-MBD: The Cardiologist’s perspectiveCharles A. Herzog, Minneapolis, USA

The Nephrologist’s perspectiveDavid C. Wheeler, London, UK

Recent changes in anaemia management practice patterns: Where are we heading? Francesco Locatelli, Lecco, Italy

Organised by AMGEN

314

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15Elicium 1

Individualization of HD therapy - the way to address clinical challenges

Chair: Claudio Ronco, Vicenza, Italy

Who benefits from HDF and why, based on recent clinical trials?Paul Cockwell, Birmingham, UK

How to prevent intradialytic hypotension while reducing volume overload?Rajiv Agarwal, Indianapolis, USA

Dialysis standard of care for high-bleeding-risk HD patients - what the HepZero study tells usMaurice Laville, Lyon, France

Organised by GAMBRO

315

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15Forum

Current and future management strategies in a changing ADPKD landscape

Chair: Albert Ong, Sheffield, UK

Introduction - Evolution and new insights into the management of ADPKDAlbert Ong, Sheffield, UK

Clinical perspectivenes on assessing the natural progression of the diseaseBertrand Knebelman, Paris, France

Current clinical management and new and emerging treatment optionsAndreas Serra, Zurich, Switzerland

Summary - A changing paradigm - what can we hope to achieve?Albert Ong, Sheffield, UK

Organised by oTSUKA PHARMACEUTICALS EURoPE

316

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15E104-107

Exploring Controversies in Iron Therapy - Looking Beyond Treating Anaemia

Chair: Carlo Gaillard, Groningen, The Netherlands

Welcome and IntroductionCarlo Gaillard, Groningen, The Netherlands

Controversies in Diagnosis and Treatment of Iron Deficiency in Patients With CKDIain Macdougall, London, UK

Targeting Higher Serum Ferritin With Intravenous Ferric Carboxymaltose in Patients With ND-CKD Not Receiving ESA - The FIND-CKD StudySimon Roger, Gosford, Australia

Benefits of Treating Iron Deficiency in Patients With or Without AnaemiaAdriaan Voors, Groningen, The Netherlands

Panel DiscussionCarlo Gaillard, Groningen, The Netherlands

Organised by VIFoR FRESENIUS MEDICAL CARE RENAL PHARMA

317

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15G106-107

A New Frontier in CKD Anemia Understanding: the interlinking roles of Inflammation, FGF-23, and Oral Iron

Chairs: David Goldsmith, London, UK Christoph Wanner, Würzburg, Germany

A Silent Killer - The Role of IV Iron in Inflammation in Kidney DiseasePeter Stenvinkel, Stockholm, Sweden

Emerging CKD Clinical Markers - a Discussion of FGF-23 and IronMyles S. Wolf, Chicago, USA

The role of Oral Iron in the Optimization of Anaemia Management in CKDSteve Fishbane, New York, USA

Panel Discussion

Organised by KERYx BIoPHARMACEUTICALS

318

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15G104-105

Optimal Therapy of SHPT: Is it Possible?

Chairs: Marc Vervloet, Amsterdam, The Netherlands Armando L. Negri, Buenos Aires, Argentina

Lessons learned from VITAL, IMPACT and PRIMODaniel Coyne, St. Louis, USA

Measuring PTH: How SHPT treatment is affected by the assay used and type of PTH measured Berthold Hocher, Potsdam, Germany

When VitD treatment fails; what is next?Mario Cozzolino, Milan, Italy

Question and answer

Organised by ABBVIE

319

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 13:15 - 15:15G102-103

Dialysis treatment: Status and factors to improve

Chair: Jürgen Floege, Aachen, Germany

Treatment reality in 2014 in Europe - are we on the right track? Results from the DOPPS. Friedrich K. Port, Ann Arbor, USA

How to optimize dialysis therapy in times of cost reduction? Andrew Davenport, London, UK

HDF as a future therapy? Johannes Mann, Munich, Germany

Organised by B.BRAUN

320

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Sunday, June 1, 2014 18:45 - 19:45G102-103

Diagnostic challenges in identifying causes of TMA

Chair: Dirk Kuypers, Leuven, Belgium

Welcome and introduction to TMADirk Kuypers, Leuven, Belgium

Differential diagnosis of TMA: a case based reviewJosep M. Campistol, Barcelona, Spain

Management of aHUS in 2014Christophe Legendre, Paris, France

ConclusionQuestions and answers

Organised by ALExIoN PHARMA INTERNATIoNAL

321

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 06:45 - 07:45G104-105

A Tale of Two Nephropathies: The AKI-CKD Paradox

Chair: Dick de Zeeuw, Groningen, The Netherlands

Welcome and introduction

The two faces of GFR decline: When is a decrease in eGFR beneficial?Hiddo Lambers Heerspink, Groningen, The Netherlands

Ongoing research in the prevention and management of AKIAndrew Lewington, Leeds, UK

Ongoing research in the prevention and management of CKDDick de Zeeuw, Groningen, The Netherlands

Question and answer

Organised by ABBVIE

322

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15Auditorium

Why does the world need another phosphate binder?

Chairs: Mariano Rodriguez, Cordoba, Spain Mario Cozzolino, Milano, Italy

Phosphate and nutrition in the dialysis patient - reasons to interveneDenis Fouque, Lyon, France

The importance of adherence in drug treatment for a CKD patientAdrian Covic, Iasi, Romania

New options for phosphate control achieved with a minimum of pillsMarkus Ketteler, Coburg, Germany

Organised by FRESENIUS MEDICAL CARE RENAL PHARMA

323

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15Elicium 2

Bringing the Benefits of High Dose Haemodialysis to the Home with a Novel Haemodialysis System

Chair: Pieter ter Wee, Amsterdam, The Netherlands

Dialysis Inadequacy – Understanding the Limitations of Conventional HaemodialysisChristopher McIntyre, Nottingham, UK

Improving Clinical Endpoints and Health-Related Quality of Life with High Dose Haemo-dialysisTom Cornelis, Maastricht, The Netherlands

Overcoming Barriers to the Growth of Home Haemodialysis through Device InnovationBruce Culleton, Chicago, USA

Organised by BAxTER

324

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15Elicium 1

Healthy Kidneys, Bones, and Heart: The Cardio-Endocrine-Renal Connection, and Risk Reduction in the CKD-MBD Patient

Chair: Michel Jadoul, Brussels, Belgium

Calcium Homeostasis - A Delicate Balance; A Cardiologist’s PerspectiveKlaus Witte, Leeds, UK

The Endocrinology Perspective on Calcium Use in Healthy Men and Women, and in those with CKDSophie Jamal, Toronto, Canada

Incorporating Phosphorus and Calcium Management Strategies into the Care of Patient with CKDGrahame Elder, Sidney, Australia

Organised by SANOFI

325

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15E104-107

Reshaping Patient Outcomes: from Science to Clinical Practice in the Management of Tube-rous Sclerosis Complex (TSC) - Associated Renal Angiomyolipoma (AML)

Chair: Bernard A. Zonnenberg, Utrecht, The Netherlands

Reshaping patient outcomes: the importance of early accurate diagnosis and adherence to guidelinesBernard A. Zonnenberg, Utrecht, The Netherlands

Bridging the gap: understanding the mTOR signaling pathway and developing targeted therapyJulian Sampson, Cardiff, UK

Optimizing long term management of adult patients with renal angiomyolipoma and TSCJ. Chris Kingswood, Brighton, UK

Organised by NOVARTIS

326

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15G106-107

Oxidative Stress as an Emerging Risk Factor in Haemodialysis. How to Manage?

Chairs: Francesco Locatelli, Lecco, Italy Peter Stenvinkel, Stockholm, Sweden

Inflammation and oxidative stress in ESRD - partners in crimePeter Stenvinkel, Stockholm, Sweden

Antioxidant and pro-oxidant imbalance in uraemic milieuJean-Paul Cristol, Montpellier, France

Clinical studies of Vitamin E bonded polysulfone dialysis membranesSimon Lines, Norwich, UK

Discussion and closing remarksFrancesco Locatelli, Lecco, Italy

Organised by ASAHI KASEI MEDICAL

327

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15G104-105

New comparative clinical data on intravenous iron in CKD patients

Chair: Andrzej Wiecek, Katowice, Poland

New data: Are IV-iron preparations toxic to the patients?Gunnar Heine, Homburg, Germany

New randomised comparative efficacy study data between intravenous iron compounds, iso-maltoside 1000 and iron sucrose in CKD patients on dialysisSunil Bhandari, Hull, UK

High dose intravenous iron efficacy and safety with IV Iron isomaltoside 1000 in pre-dialysis CKD patientsPhilip Kalra, Salford, UK

Organised by PHARMACoSMoS

328

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15G102-103

Hyperkalemia: Old Foe with New Faces

Chair: Peter A. McCullough, Dallas, USA

Current Epidemiology of HyperkalemiaCsaba P. Kovesdy, Memphis, USA

Hyperkalemia and Cardiorenal DisordersPeter A. McCullough, Dallas, USA

Standard and Emerging TreatmentDavid Goldsmith, London, UK

Supported by ZS PHARMACEUTICALS

329

InduS

try Sp

onSo

red S

yMpo

SIa

w w w . e r a e d t a 2 0 1 4 . o r g

Industry Sponsored Symposia

Monday, June 2, 2014 13:15 - 15:15Emerald

The new frontier of Immunosuppression: the fast, stable, round-the-clock graft protection

Chair: Teun Van Gelder, Rotterdam, The Netherlands

IntroductionTeun Van Gelder, Rotterdam, The Netherlands

Tailoring pharmacokinetics for kidney transplant patientsPierre Marquet, Limoges, France

Improving immunosuppressive treatments: from clinical trials to clinical practiceJosep M. Grinyó, Barcelona, Spain

Discussion and summaryTeun Van Gelder, Rotterdam, The Netherlands

Organised by CHIESI FARMACEUTICI